• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Imatinib resistance due to a novel and rare class of mutation at position S348 (1043nt C→A) of Bcr/Abl gene in a chronic myeloid leukemia patient.

作者信息

Dhangar Somprakash, C Selvaa Kumar, S Chandrakala, Vundinti Babu Rao

机构信息

Department of Cytogenetics, 13th Floor, National Institute of Immuno- Haematology, KEM Hospital Campus, Parel, Mumbai, 400 012, Maharashtra, India.

School of Biotechnology and Bioinformatics, Level 6, D.Y. Patil University, Sector 15, Plot No. 50, CBD Belapur, Navi Mumbai, 400 614, Maharashtra, India.

出版信息

Leuk Res. 2018 Sep;72:96-98. doi: 10.1016/j.leukres.2018.08.008. Epub 2018 Aug 11.

DOI:10.1016/j.leukres.2018.08.008
PMID:30118898
Abstract
摘要

相似文献

1
Imatinib resistance due to a novel and rare class of mutation at position S348 (1043nt C→A) of Bcr/Abl gene in a chronic myeloid leukemia patient.一名慢性髓性白血病患者因Bcr/Abl基因第S348位（1043nt C→A）发生一类新型罕见突变导致伊马替尼耐药。
Leuk Res. 2018 Sep;72:96-98. doi: 10.1016/j.leukres.2018.08.008. Epub 2018 Aug 11.
2
Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.来自印度的慢性髓性白血病患者中对伊马替尼疑似耐药的BCR-ABL激酶结构域突变谱——突变罕见且分布各异。
Leuk Lymphoma. 2009 Dec;50(12):2092-5. doi: 10.3109/10428190903332486.
3
Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.一名慢性髓性白血病患者携带新型e8a2 BCR-ABL转录本变体，对甲磺酸伊马替尼耐药。
Acta Haematol. 2008;120(3):146-9. doi: 10.1159/000178145. Epub 2008 Nov 28.
4
Imatinib resistance in chronic myeloid leukemia due to a rare mutation.慢性髓性白血病中因罕见突变导致的伊马替尼耐药
Leuk Lymphoma. 2017 Jul;58(7):1750-1752. doi: 10.1080/10428194.2016.1256479. Epub 2016 Nov 20.
5
Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.
Leuk Lymphoma. 2014 Jul;55(7):1684-6. doi: 10.3109/10428194.2013.850164. Epub 2013 Nov 14.
6
Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.显示耐药机制的伊马替尼耐药K562细胞系的特征分析
Cell Mol Biol (Noisy-le-grand). 2018 May 15;64(6):23-30.
7
Mutations in ABL kinase domain are associated with inferior progression-free survival.ABL 激酶结构域的突变与较差的无进展生存期相关。
Leuk Lymphoma. 2010 Jun;51(6):1072-8. doi: 10.3109/10428191003729741.
8
PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.PBA2，一种针对慢性髓性白血病中伊马替尼耐药的BCR-ABL T315I突变的新型抑制剂。
Cancer Lett. 2016 Dec 28;383(2):220-229. doi: 10.1016/j.canlet.2016.09.025. Epub 2016 Oct 5.
9
CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.CD-200可诱导T315I突变的伊马替尼耐药慢性髓性白血病细胞凋亡并抑制Bcr-Abl信号传导。
Int J Oncol. 2015 Jul;47(1):253-61. doi: 10.3892/ijo.2015.2994. Epub 2015 May 11.
10
Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.并非所有慢性粒细胞白血病中的伊马替尼耐药都是由BCR-ABL激酶结构域突变引起的。
Ann Hematol. 2006 Dec;85(12):841-7. doi: 10.1007/s00277-006-0171-8. Epub 2006 Sep 28.